Related Experiment Video
Updated: Jan 24, 2026

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows
Chihoko Yoshimura1, Hiromi Muraoka2, Hiroaki Ochiiwa2
1Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan. chihoko-yoshimura@taiho.co.jp.
Abstract:
NEDD8-activating enzyme (NAE) is an essential E1 enzyme of the NEDD8 conjugation (neddylation) pathway, which controls cancer cell growth and survival through activation of cullin-RING ubiquitin ligase complexes (CRL). In this study, we describe the preclinical profile of a novel, highly potent, and selective NAE inhibitor, TAS4464. TAS4464 selectively inhibited NAE relative to the other E1s UAE and SAE. TAS4464 treatment inhibited cullin neddylation and subsequently induced the accumulation of CRL substrates such as CDT1, p27, and phosphorylated IκBα in human cancer cell lines. TAS4464 showed greater inhibitory effects than those of the known NAE inhibitor MLN4924 both in enzyme assay and in cells. Cytotoxicity profiling revealed that TAS4464 is highly potent with widespread antiproliferative activity not only for cancer cell lines, but also patient-derived tumor cells. TAS4464 showed prolonged target inhibition in human tumor xenograft mouse models; weekly or twice a week TAS4464 administration led to prominent antitumor activity in multiple human tumor xenograft mouse models including both hematologic and solid tumors without marked weight loss. As a conclusion, TAS4464 is the most potent and highly selective NAE inhibitor reported to date, showing superior antitumor activity with prolonged target inhibition. It is, therefore, a promising agent for the treatment of a variety of tumors including both hematologic and solid tumors. These results support the clinical evaluation of TAS4464 in hematologic and solid tumors.
Insights
TAS4464 is a potent and selective inhibitor of NEDD8-activating enzyme (NAE), a key target in cancer. This novel compound demonstrated significant antitumor activity in preclinical models, supporting its clinical evaluation for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The NEDD8-activating enzyme (NAE) is crucial for the neddylation pathway, regulating cancer cell proliferation and survival via cullin-RING ubiquitin ligase (CRL) complexes.
- Targeting NAE offers a potential therapeutic strategy for cancer treatment.
Purpose of the Study:
- To evaluate the preclinical profile of TAS4464, a novel, potent, and selective NAE inhibitor.
- To compare TAS4464's efficacy against the established NAE inhibitor MLN4924.
Main Methods:
- In vitro enzyme assays and cell-based assays to assess NAE inhibition and downstream effects.
- Cytotoxicity profiling in various cancer cell lines and patient-derived tumor cells.
- In vivo studies using human tumor xenograft mouse models to evaluate antitumor activity and target inhibition.
Main Results:
- TAS4464 demonstrated high selectivity for NAE over other E1 enzymes (UAE, SAE).
- TAS4464 effectively inhibited cullin neddylation, leading to the accumulation of CRL substrates and potent antiproliferative effects.
- TAS4464 exhibited superior efficacy compared to MLN4924 in vitro and in vivo, with significant antitumor activity in hematologic and solid tumors without notable toxicity.
Conclusions:
- TAS4464 represents a highly potent and selective NAE inhibitor with promising preclinical antitumor activity.
- Its ability to achieve prolonged target inhibition and broad efficacy supports its potential as a therapeutic agent for diverse cancers.
- Clinical evaluation of TAS4464 in both hematologic and solid tumors is warranted.
Related Concept Videos
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzymes and Activation Energy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
tRNA Activation
Co-activators and Co-repressors
Activation Energy

